Shape Therapeutics’ Big Financing Shows Growing Interest In Novel Capsids

Several companies have recently raised large amounts of money from venture capital as well as potentially through partnerships for next-generation capsid technology.

Horizontal image of a collection of prescription capsules and tablets in the shape of DNA running diagonally across the picture on a light green background with room for copy (text). — Shape Therapeutics said it raised $116m in a series B venture capital round • Source: Shutterstock

Shape Therapeutics, Inc. is the latest gene therapy-focused company to raise a large amount of capital with the aim of developing adeno-associated viral (AAV) vector-based gene therapies that offer improvements over existing products.

Seattle-based ShapeTx said on 15 July that it completed a $112m series B venture capital round, which it plans to use to develop RNA

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Hengrui Set For Biggest Biopharma IPO So Far This Year

15 May 2025

• By Dexter Jie Yan

Jiangsu Hengrui Pharmaceuticals is gearing up for what will be 2025's biggest biopharma IPO so far, hoping to raise up to $1.27bn on the Hong Kong Stock Exchange. China's top drug maker by pipeline size plans to use part of the proceeds to reboot its overseas clinical trials ambitions.

Finance Watch: Funding Alternatives Become The Norm In Tough Public Markets

13 May 2025

• By Mandy Jackson

Public Company Edition: With fewer follow-on offerings, drug developers are pursuing other options. Axsome accessed up to $570m in debt, Evolus obtained $250m in a new credit facility and Abeona raised $155m from a PRV sale, but Apimeds was able to execute a small $13.5m IPO.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

13 May 2025

• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.